EZH2 and cancer: Furthermore, overexpression of EZH2 is correlated with inferior patient outcomes in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), also making EZH2 a particularly attractive epigenetic therapeutic target in this cancer type [153].